| Literature DB >> 36119332 |
Aliza Mittal1, Pallavi Nadig1, Kuldeep Singh1.
Abstract
Acute kidney injury (AKI) is an important factor affecting the outcome of hospitalized patients under any disease condition. While a lot has been said and studied about pulmonary manifestations of COVID-19 and multisystem inflammatory syndrome in children, this review focuses on its renal manifestations in children with and its complications. For the collection of data, the patient intervention control outcome model was applied to determine all eligible studies. The data was extracted using PubMed/Medline, Embase, and Google Scholar databases using a combination of keywords (AKI, renal failure, kidney disease, children, pediatric, covid-19, SARS COv2). Studies were reviewed after the exclusion of duplicates. The incidence of renal involvement in COVID 19 is up to 10-15%, which is higher than SARS. Both direct and indirect pathogenic mechanisms operate in patients with COVID 19 leading to varied manifestations. While AKI remains the most common manifestation in children admitted to intensive care units, other manifestations like, proteinuria, hematuria, rhabdomyolysis, and thrombotic microangiopathy have also been described in the literature. The children already on immunosuppression due to transplant or immune-mediated renal disorders do not seem to have more severe illness than those without it. The principles of management of AKI in COVID have not been different than other patient groups. Copyright:Entities:
Keywords: Acute kidney injury; COVID-19; immunosuppression; thrombotic microangiopathy
Year: 2022 PMID: 36119332 PMCID: PMC9480659 DOI: 10.4103/jfmpc.jfmpc_1777_21
Source DB: PubMed Journal: J Family Med Prim Care ISSN: 2249-4863
Figure 1Pathogenic factors leading to renal injury in COVID-19. The flow diagram depicts direct disease factors as well as treatment-related factors that may cause renal injury
Potential risk factors for AKI in COVID-19 in children
| Pre-existing comorbidities | At admission | During hospitalization |
|---|---|---|
| Congenital Heart disease | GI Losses | Fluid overload |
| Congenital kidney disease | Requirement of ventilation | Nephrotoxic drugs |
| Diabetes | Dehydration | High PEEP requirement |
| Post-transplant state/immunosuppression | Rhabdomyolysis | Worsening pneumonia or myocarditis (organ cross talk) |
| Urological disorders | Elevated inflammatory markers- Hypercoagulability, microangiopathy, and endothelial dysfunction | Requirement of vasopressors |
| Genetic factors (APOL1, African ancestry) | Severe SARS-CoV2 Pneumonia | Medication-induced Interstitial nephritis/crystalline nephropathy |
Figure 2SARS-CoV2 directly infects cells bearing the ACE2 receptors (endothelial cells, alveolar cells, intestinal cells, and smooth muscles.) and the TMPRSS2 (Transmembrane serine protease 2) receptors (located in podocytes and proximal straight tubular cells) and is internalized into the host cell. The virus then uses the host machinery and replicates within the host cell leading to direct viral tropic damage. In the kidneys, it has a propensity for tubular cells. ACE 2 depletion inhibits the conversion of Angiotensin 2 to Angiotensin 1-7 (Ang 1-7), the vasoactive ligand for the MAS receptor and is responsible for Antithrombotic signals. Increased activation of Type 1 Angiotensin receptor occurs due to pro-inflammatory signals produced by reduced MAS. Additionally, reduction in ACE 2 that limits the formation of Ang 1-7 from Ang 2 leads to increased activation of AT1R (Angiotensin 1 receptor). Also, there is reduced conversion of Des-Arginine Bradykinin to inactive peptides, and hence activation of Bradykinin receptors takes place, all of which tilts the balance towards a pro-thrombotic milieu. SARS-CoV2 activates the complement system by classical, lectin as well as alternate pathway. Hence, the generation of C3 convertases and downstream pathways leads to membrane attack complex formation on the target cells. The release of adhesion molecules like ICAM, VCAM, VAP-1, and selectins lead to leucocyte recruitment, and the release of cytokines and chemokines accentuates endothelial injury. AT1R produces reactive oxygen species, which can cause direct endothelial damage, while reduced production of NO and MAS lead to vasoconstriction. This conglomeration of endothelial damage, vasoconstriction, and leucocyte recruitment leads to endothelial dysfunction. The activated endothelial cells initiate coagulation and massive platelet binding, formation of fibrin, and clotting of RBC’s leading to systemic thrombosis and Disseminated Intravascular Coagulation